Abstract: Epigenetic compound screening platform, including methods and cell lines. In an exemplary screening method, ADK-null, ADK-L, and ADK-S cell lines may be selected. The ADK-null cell line may express no ADK protein. The ADK-L cell line may express only the long (L), nuclear isoform of a mammalian ADK protein from an exogenous construct. The ADK-S cell line may express only the short (S), cytoplasmic isoform of a mammalian ADK protein from an exogenous construct. Each of the cell lines may be exposed to the same test compound. A level of DNA or histone methylation, or DNA or histone methyltransferase activity for each of the exposed cell lines may be measured. The level for each exposed cell line may be compared to a corresponding level measured without exposure to the test compound, to determine whether the test compound affects DNA or histone methylation, or DNA or histone methyltransferase activity, in any of the cell lines.

Abstract: Methods of anti-epileptogenesis treatment in which adenosine kinase (ADK) activity or expression is inhibited only transiently to provide a long-term benefit to a non-epileptic or epileptic subject. In an exemplary method, a therapeutically effective amount of an ADK inhibitor may be administered to a human non-epileptic subject over a finite, predetermined treatment period having a duration of less than two months. The non-epileptic subject may have sustained a precipitating event with a known risk to trigger latent development of an acquired form of epilepsy. Administration of the ADK inhibitor to the subject may be stopped at the end of the treatment period for at least the longer of (i) six months and (ii) ten times the duration of the treatment period. The step of administering may reduce the chance of the subject having seizures caused by the acquired form of epilepsy for an extended period following the end of the treatment period.